Akeso, Inc. (AKESF)
OTCMKTS · Delayed Price · Currency is USD
12.81
0.00 (0.00%)
Feb 11, 2026, 4:00 PM EST
Akeso Employees
Akeso had 3,529 employees as of June 30, 2025. The number of employees increased by 494 or 16.28% since the number was reported on December 31, 2024.
Employees
3,529
Change
494
Growth
16.28%
Revenue / Employee
$99,313
Profits / Employee
-$33,464
Market Cap
12.40B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 3,529 | 494 | 16.28% |
| Dec 31, 2024 | 3,035 | 257 | 9.25% |
| Dec 31, 2023 | 2,778 | 437 | 18.67% |
| Dec 31, 2022 | 2,341 | 476 | 25.52% |
| Dec 31, 2021 | 1,865 | 1,119 | 150.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Silence Therapeutics | 116 |
| Vaxart | 105 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| Nuo Therapeutics | 9 |
| ZIVO Bioscience | 7 |
| Vicapsys Life Sciences | 2 |
| Cell Source | 1 |
Akeso News
- 6 days ago - Akeso Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer - PRNewsWire
- 23 days ago - Akeso Announces NMPA Acceptance of Second NDA for Gumokimab (IL-17A Inhibitor) in Active Ankylosing Spondylitis - PRNewsWire
- 2 months ago - All Approved Indications of Five Akeso's Innovative Drugs Included in China's Latest NRDL: Featuring Two First-in-Class Bispecifics with New First-Line Indications and Three Newly Negotiated Drugs - PRNewsWire
- 2 months ago - Summit C-Suite Risks Success, Akeso Wins Either Way - Seeking Alpha
- 3 months ago - Akeso's Bispecific Antibody Targeting Aβ and BBB-Expressed Receptor Approved for Alzheimer's Disease Clinical Trials in China - PRNewsWire
- 3 months ago - Akeso Announces First Patient Dosed in Phase I Trial of Personalized mRNA Vaccine AK154 as Monotherapy or in Combination with Cadonilimab or Ivonescimab for Adjuvant Treatment of Pancreatic Cancer - PRNewsWire
- 3 months ago - Akeso Unveils Promising Preclinical Data for IL-1RAP Targeting Antibody (AK135) at SITC 2025 - PRNewsWire
- 3 months ago - Akeso's Ivonescimab Secures Fourth Breakthrough Therapy Designation in China for First-Line Treatment of Triple-Negative Breast Cancer - PRNewsWire